North American Biologicals, Inc.
This article was originally published in The Gray Sheet
Announces a public offering of 4.2 mil. shares of common stock. The Miami, Florida-based provider of human blood plasma elements and plasma/sera-based diagnostic products will offer 2.7 mil. shares, and two selling shareholders will offer 1.5 mil. Assuming the company's planned selling price of $6.50 per share, NABI will gain net proceeds of approximately $15.5 mil. through its 2.7 mil. shares. Additional proceeds could be realized through the sale of 630,000 over-allotment shares by underwriters Raymond James-& Associates and NatWest Securities Limited.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.